Morrow Sodali advisor on the Pfizer - Medivation acquisition
30 August 2016 Articles
Morrow Sodali will act as Information Agent in the Pfizer - Medivation M&A deal.
The Companies have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
Related News
Sodali & Co Concludes 2024 with Milestone in Sovereign Debt Restructuring
10 January 2025
What to Expect from Shareholder Meetings in 2025
02 January 2025
The Seeds of Shareholder Discord in 2024: Executive Remuneration and ESG Targets
27 December 2024
The Growing Backlash to DEI and ESG in the U.S. Is Affecting Canadian Companies as Well
12 December 2024
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right